Skip to main contentAI and Advanced
/
SUDEEPPHRM · NSEBSE SENSEX76,132.81-0.50%BSE |
NIFTY 5023,779.15-0.50%NSE |
NIFTY BANK57,088.3-0.49%NSE |
NIFTY IT29,995.2-2.28%NSE |
NIFTY AUTO27,698.75-0.04%NSE |
NIFTY FMCG45,592.15-0.66%NSE |
NIFTY PHARMA26,675.5+0.75%NSE |
NIFTY 50023,156.2-0.42%NSE |
SU
NSE · Equity shares · Biotechnology & Drugs-6.00 · -0.45%
Sudeep Pharma SUDEEPPHRM
NSE:INR 1,323.3
BSE:INR 1,323.9
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SUDEEPPHRM
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,329.3
Day rangeINR 1,305 — INR 1,378
52-week rangeINR 524.05 — INR 1,378
Volume2.08 L
Market cap11,177.78
P/E38.25
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)638.8
Net Income (INR Cr)172.89
P/E Ratio38.25
Book Value71.57
EPS15.5
Price/BV18.49Computed
Research path: Interpret Sudeep Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SUDEEPPHRMSudeep Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,174.88 | 717.17 | 513.87 |
| Accumulated Depreciation Total | -41.12 | -26.34 | -16.74 |
| Cash Equivalents | 0.18 | 0.01 | 0.42 |
| Other Liabilities Total | 29.8 | 1.75 | 1.32 |
| Accrued Expenses | 4.44 | 3.42 | 3.09 |
| Long Term Debt | 34.29 | 38.96 | 10.24 |
| Common Stock Total | 11.29 | 9.72 | 1.41 |
| Other Equity Total | -5.68 | -2.18 | -3.07 |
| Other Current Assets Total | 2.62 | 2.35 | 0.67 |
| Prepaid Expenses | 5.65 | 8.83 | 1.85 |
| Total Assets | 1,174.88 | 717.17 | 513.87 |
| Current Portof LT Debt/Capital Leases | 12.74 | 10.66 | 10.43 |
| Additional Paid-In Capital | 249.02 | 0 | 9.86 |
| Cash | 26.56 | 36.8 | 13.56 |
| Total Equity | 883.34 | 493.09 | 356 |
| Long Term Investments | 15.02 | 0.33 | 0.32 |
| Retained Earnings(Accumulated Deficit) | 628.7 | 485.55 | 347.8 |
| Total Common Shares Outstanding | 11.29 | 11.29 | 11.29 |
| Property/Plant/Equipment Total-Gross | 488.05 | 303.68 | 241.33 |
| Tangible Book Valueper Share Common Eq | 71.57 | 43.64 | 31.49 |
| Goodwill Net | 68.24 | Not available | Not available |
| Total Liabilities | 291.54 | 224.08 | 157.87 |
| Total Debt | 150.24 | 137.16 | 78.61 |
| Short Term Investments | 87.91 | 15.14 | 0.13 |
| Cashand Short Term Investments | 114.65 | 51.94 | 14.1 |
| Total Receivables Net | 272.11 | 217.78 | 169.05 |
| Notes Payable/Short Term Debt | 101.88 | 85.29 | 54.73 |
| Deferred Income Tax | 9.4 | 6.36 | 5.85 |
| Accounts Receivable-Trade Net | 227.54 | 185.35 | 144.57 |
| Property/Plant/Equipment Total-Net | 446.93 | 277.34 | 224.59 |
| Minority Interest | 14.75 | Not available | Not available |
| Total Current Liabilities | 201.96 | 174.76 | 137.26 |
| Total Inventory | 228.95 | 143.21 | 89.7 |
| Accounts Payable | 68.43 | 60.48 | 50.71 |
| Other Currentliabilities Total | 14.48 | 14.9 | 18.3 |
| Total Long Term Debt | 35.62 | 41.21 | 13.44 |
| Intangibles Net | 6.75 | 0.21 | 0.3 |
| Other Long Term Assets Total | 5.04 | 4.19 | 2.89 |
| Note Receivable-Long Term | 8.93 | 10.98 | 10.4 |
| Total Current Assets | 623.97 | 424.12 | 275.37 |
| Capital Lease Obligations | 1.34 | 2.25 | 3.2 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.51
Price to Sale Ratio17.50
Margins
Operating Margin 12m32.24
Net Profit Margin 12m27.14
Yield
Dividend Yield %0.16
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk43.84
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 76.15%
- FII
- 1.81%
- MF
- 5.47%
- Other
- 16.57%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Stock market today: Trade setup for Nifty 50, India VIX to ICICI Prudential AMC IPO — eight stocks to buy or sellMarket news · 19 Dec 2025, 8:38 am
Stock market today: Experts have recommended eight stocks to buy today — GMDC, Hindustan Copper, Sudeep Pharma, Bank of Baroda, Divi's Lab, HBL Engineering, BSE, and Firstcry
Stock market today: Trade setup for Nifty 50 to USD vs INR, eight stocks to buy or sell on Wednesday — 17 December 2025Market news · 17 Dec 2025, 8:49 am
Stock market today: Experts have recommended eight stocks to buy today — AIIL, titan, Sudeep Pharma, PG Electroplast, NTPC, Rallis India, Astral, and Dishman Carbogen
Sudeep Pharma share price extends rally after strong listing. Should investors buy, sell or hold the stock?Market news · 28 Nov 2025, 12:43 pm
Sudeep Pharma IPO listing was better than Street estimates as was indicated by the grey market premium (GMP). Ahead of the debut, Sudeep Pharma IPO GMP today signalled a listing gain of nearly 20%.
Stellar Debut! Sudeep Pharma share price lists at <span class='webrupee'>₹</span>730 on NSE, a premium of 23.10% from IPO priceMarket news · 28 Nov 2025, 9:58 am
Sudeep Pharma shares debuted strongly on November 28, listing at ₹ 730 on NSE and ₹ 733.95 on BSE, both showing significant premiums. The IPO, which raised ₹ 895 crore, was oversubscribed 93.71 times, with notable interest from retail and institutional investors.
Sudeep Pharma IPO listing date today. GMP, experts signal strong debut of shares in Indian stock marketMarket news · 28 Nov 2025, 6:51 am
Sudeep Pharma IPO listing date is today, November 28, and the shares will be listed on BSE and NSE. Ahead of the share debut, Sudeep Pharma IPO GMP today and analysts indicate a strong listing of shares in Indian stock market today.
Sudeep Pharma IPO listing date tomorrow. Here’s what GMP signals about the share debut on Dalal StreetMarket news · 27 Nov 2025, 3:11 pm
Sudeep Pharma IPO listing date is November 28, and the equity shares will be listed on BSE and NSE. Ahead of the share debut, Sudeep Pharma IPO GMP today signals a strong debut of shares on Dalal Street.
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.5000 per share(150%)Final Dividend
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
ShareKeyX Community
Discussion and sentiment for Sudeep Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Sudeep Pharma Private Limited is an India-based manufacturing pharmaceutical and nutraceutical products company. The Company is engaged in business of manufacturing and selling pharmaceutical and food, nutrition and specialty ingredients and intermediaries, used by pharmaceutical, food and nutrition industries globally. The Company a wide range of products, including mineral salts such as calcium salts, zinc salts, iron salts, potassium salts, magnesium salts, sodium salts, simethicone salts and copper salts. It offers products to a wide range of markets, which includes pharmaceuticals, dietary health, infant nutrition, beverage, dairy products, bakery products, confectionery, and staple food markets. Its subsidiaries include Sudeep Nutrition Private Limited, Sudeep Pharma USA Inc., Sudeep Pharma B.V., and Sudeep Advanced Materials Private Limited.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SUDEEPPHRM
- BSE Code
- 544619
Questions
Stock FAQ
What is the symbol and ISIN of Sudeep Pharma?
Sudeep Pharma has the symbol SUDEEPPHRM and ISIN - INE0QPI01025.
What is the current price of Sudeep Pharma?
Sudeep Pharma is currently trading at INR 1,323.30.
What are the year high and year low of Sudeep Pharma?
Sudeep Pharma has a year high of INR 1,378.00 and a year low of INR 524.05.
What is the market capitalization of Sudeep Pharma?
Sudeep Pharma has a market capitalization of INR 11,177.78 crore.
What is the P/E ratio of Sudeep Pharma?
Sudeep Pharma has a P/E ratio of 38.25.
What is the dividend yield of Sudeep Pharma?
Sudeep Pharma has a dividend yield of 0.16%.
How is the financial performance of Sudeep Pharma based on revenue, net income, and EPS?
Sudeep Pharma has revenue of INR 638.80 crore, net income of INR 172.89 crore, and EPS of INR 15.49.
What is the book value of Sudeep Pharma?
Sudeep Pharma has a book value of INR 71.57.
What is the debt-to-equity ratio of Sudeep Pharma?
Sudeep Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Sudeep Pharma?
Sudeep Pharma has a price-to-book ratio of 18.49 and a price-to-sales ratio of 17.50.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.